These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 19762120

  • 1. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus.
    Menzin J, Marton JP, Meyers JL, Carson RT, Rothermel CD, Friedman M.
    Am J Infect Control; 2010 Feb; 38(1):44-9. PubMed ID: 19762120
    [Abstract] [Full Text] [Related]

  • 2. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS, Sorensen SV, Liu LZ, Itani KM.
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis.
    Bounthavong M, Zargarzadeh A, Hsu DI, Vanness DJ.
    Value Health; 2011 Jun; 14(5):631-9. PubMed ID: 21839399
    [Abstract] [Full Text] [Related]

  • 4. Costs of skin and skin structure infections due to Staphylococcus aureus: an analysis of managed-care claims.
    Marton JP, Jackel JL, Carson RT, Rothermel CD, Friedman M, Menzin J.
    Curr Med Res Opin; 2008 Oct; 24(10):2821-8. PubMed ID: 18759996
    [Abstract] [Full Text] [Related]

  • 5. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
    Davis SL, McKinnon PS, Hall LM, Delgado G, Rose W, Wilson RF, Rybak MJ.
    Pharmacotherapy; 2007 Dec; 27(12):1611-8. PubMed ID: 18041881
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
    McCollum M, Sorensen SV, Liu LZ.
    Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468
    [Abstract] [Full Text] [Related]

  • 8. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria.
    Eckmann C, Lawson W, Nathwani D, Solem CT, Stephens JM, Macahilig C, Simoneau D, Hajek P, Charbonneau C, Chambers R, Li JZ, Haider S.
    Int J Antimicrob Agents; 2014 Jul; 44(1):56-64. PubMed ID: 24928311
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany.
    Schürmann D, Sorensen SV, De Cock E, Duttagupta S, Resch A.
    Eur J Health Econ; 2009 Feb; 10(1):65-79. PubMed ID: 18437437
    [Abstract] [Full Text] [Related]

  • 10. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
    Sakoulas G, Brown J, Lamp KC, Friedrich LV, Lindfield KC.
    Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
    Campbell ML, Marchaim D, Pogue JM, Sunkara B, Bheemreddy S, Bathina P, Pulluru H, Chugh N, Wilson MN, Moshos J, Ku K, Hayakawa K, Martin ET, Lephart PR, Rybak MJ, Kaye KS.
    Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections.
    Bounthavong M, Hsu DI.
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):683-98. PubMed ID: 23252352
    [Abstract] [Full Text] [Related]

  • 14. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
    Jahoda D, Nyc O, Pokorný D, Landor I, Sosna A.
    Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Usery JB, Vo NH, Finch CK, Cleveland KO, Gelfand MS, Self TH.
    Am J Med Sci; 2015 Jan; 349(1):36-41. PubMed ID: 25233042
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model.
    Bounthavong M, Hsu DI, Okamoto MP.
    Int J Clin Pract; 2009 Mar; 63(3):376-86. PubMed ID: 19222624
    [Abstract] [Full Text] [Related]

  • 18. [Pharmacoeconomic assessment of daptomycin as first-line therapy for bacteraemia and complicated skin and skin structure infections caused by gram-positive pathogens in Spain].
    Grau S, Rebollo P, Cuervo J, Gil-Parrado S.
    Rev Esp Quimioter; 2011 Sep; 24(3):154-63. PubMed ID: 21947099
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.